Advancing How We Learn from Biodesign to Mitigate Risks with Next-Generation Genome Engineering

Paul E. Abraham; Jessy L. Labbé; Amber A. McBride

doi:10.34133/2020/9429650

Advancing How We Learn from Biodesign to Mitigate Risks with Next-Generation Genome Engineering

Paul E. Abraham, Jessy L. Labbé, Amber A. McBride

Bioanalytical Mass Spectrometry

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

In the last decade, the unprecedented simplicity and flexibility of the CRISPR-Cas system has made it the dominant transformative tool in gene and genome editing. However, this democratized technology is both a boon and a bane, for which we have yet to understand the full potential to investigate and rewrite genomes (also named “genome biodesign”). Rapid CRISPR advances in a range of applications in basic research, agriculture, and clinical applications pose new risks and raise several biosecurity concerns. In such a fast-moving field of research, we emphasize the importance of properly communicating the quality and accuracy of results and recommend new reporting requirements for results derived from next-generation genome engineering.

Original language	English
Article number	9429650
Journal	BioDesign Research
Volume	2020
DOIs	https://doi.org/10.34133/2020/9429650
State	Published - 2020

Funding

This work was supported by the U.S. Department of Energy (DOE), Office of Biological and Environmental Research (BER) and the Genomic Sciences Program as a part of the Secure Biosystems Design program. The manuscript has been authored by UT-Battelle, LLC, under contract no. DE-AC05-00OR22725 with the U.S. Department of Energy. This manuscript has been authored by UT-Battelle, LLC under contract no. DE-AC05-00OR22725 with the U.S. Department of Energy. The United States Government retains and the publisher, by accepting the article for publication, acknowledges that the United States Government retains a nonexclusive, paid-up, irrevocable, worldwide license to publish or reproduce the published form of this manuscript, or allow others to do so, for United States Government purposes. The Department of Energy will provide public access to these results of federally sponsored research in accordance with the DOE Public Access Plan (http://energy.gov/downloads/doe-public-access-plan).

Funders	Funder number
U.S. Department of Energy
Biological and Environmental Research	DE-AC05-00OR22725

Access to Document

10.34133/2020/9429650

Cite this

@article{c63831b4b3a941cf95f8a0d4420a6731,

title = "Advancing How We Learn from Biodesign to Mitigate Risks with Next-Generation Genome Engineering",

abstract = "In the last decade, the unprecedented simplicity and flexibility of the CRISPR-Cas system has made it the dominant transformative tool in gene and genome editing. However, this democratized technology is both a boon and a bane, for which we have yet to understand the full potential to investigate and rewrite genomes (also named “genome biodesign”). Rapid CRISPR advances in a range of applications in basic research, agriculture, and clinical applications pose new risks and raise several biosecurity concerns. In such a fast-moving field of research, we emphasize the importance of properly communicating the quality and accuracy of results and recommend new reporting requirements for results derived from next-generation genome engineering.",

author = "Abraham, {Paul E.} and Labb{\'e}, {Jessy L.} and McBride, {Amber A.}",

note = "Publisher Copyright: Copyright {\textcopyright} 2022 Korean Society of Otorhinolaryngology-Head and Neck Surgery.",

year = "2020",

doi = "10.34133/2020/9429650",

language = "English",

volume = "2020",

journal = "BioDesign Research",

issn = "2693-1257",

publisher = "American Association for the Advancement of Science",

}

TY - JOUR

T1 - Advancing How We Learn from Biodesign to Mitigate Risks with Next-Generation Genome Engineering

AU - Abraham, Paul E.

AU - Labbé, Jessy L.

AU - McBride, Amber A.

PY - 2020

Y1 - 2020

N2 - In the last decade, the unprecedented simplicity and flexibility of the CRISPR-Cas system has made it the dominant transformative tool in gene and genome editing. However, this democratized technology is both a boon and a bane, for which we have yet to understand the full potential to investigate and rewrite genomes (also named “genome biodesign”). Rapid CRISPR advances in a range of applications in basic research, agriculture, and clinical applications pose new risks and raise several biosecurity concerns. In such a fast-moving field of research, we emphasize the importance of properly communicating the quality and accuracy of results and recommend new reporting requirements for results derived from next-generation genome engineering.

AB - In the last decade, the unprecedented simplicity and flexibility of the CRISPR-Cas system has made it the dominant transformative tool in gene and genome editing. However, this democratized technology is both a boon and a bane, for which we have yet to understand the full potential to investigate and rewrite genomes (also named “genome biodesign”). Rapid CRISPR advances in a range of applications in basic research, agriculture, and clinical applications pose new risks and raise several biosecurity concerns. In such a fast-moving field of research, we emphasize the importance of properly communicating the quality and accuracy of results and recommend new reporting requirements for results derived from next-generation genome engineering.

UR - http://www.scopus.com/inward/record.url?scp=85121040709&partnerID=8YFLogxK

U2 - 10.34133/2020/9429650

DO - 10.34133/2020/9429650

M3 - Article

AN - SCOPUS:85121040709

SN - 2693-1257

VL - 2020

JO - BioDesign Research

JF - BioDesign Research

M1 - 9429650

ER -

Advancing How We Learn from Biodesign to Mitigate Risks with Next-Generation Genome Engineering

Abstract

Funding

Access to Document

Other files and links

Fingerprint

Cite this